The Ministry of Health plans to crack down on killer malignant
tumors over the next seven years, sources revealed on Friday.
Cutting tobacco consumption -- which will hopefully reduce cases
of lung cancer -- and extending hepatitis B inoculations among
children to prevent liver cancer are the two major ways the
ministry hopes to control the menace, which claims around 1.5
million lives annually.
Experts believed that 80 percent of lung cancer could be avoided
if the nation cut back on smoking, a move which would slash cancer
fatalities by 30 percent.
According to the ministry's recently launched National Cancer
Prevention and Control Program (2004-10), steps will also be taken
to promote a healthy diet -- crucial in preventing cancer -- and
cutting the risks of contracting the deadly condition in the
workplace.
More patients will be diagnosed and treated at an early stage,
the program says.
Most cancer cases in China are normally diagnosed at a late
stage, making the condition difficult to cure and increasing the
financial and emotional burdens on patients' families and society,
said Sun Yan, an expert with Beijing Cancer Hospital affiliated to
the Chinese Academy of Medical Sciences.
Cancer has become the biggest killer of urban Chinese people,
according to Sun.
Lung, liver, stomach, esophagus, colon/rectum, breast, cervix
and nasopharyngeal cancers frequently occur in China, making up
more than 80 percent of the total malignant tumor cases.
Ministry of Health data showed that the death rate from
malignant tumors grew by 29.42 percent in 20 years from the 1970s
to the 1990s. The nation registered some 2 million cancer patients
in 2000, with around 1.5 million dying of such illnesses in the
same year.
Cancer prevention and treatment has already become a global
issue and has drawn the attention of many nations' health
authorities, medical researchers and pharmaceutical producers.
Many world famous life science researchers and developers are
cooperating with their Chinese counterparts in a bid to find the
most effective anti-cancer medicines, said Sun.
For example, Switzerland-based world No 5 pharmaceutical company
Novartis AG is working closely with Chinese scientists to develop
new cancer medicines.
The company now has 16 cancer treatment projects, with some
undergoing clinical tests in China.
The clinical test results were discussed at the first
Asia-Pacific Summit on Oncology, sponsored by Novartis, which was
held in South China's Hainan Province at the end of last month.
Hundreds of medical professionals attended the event and shared
their new findings on cancer research.
The company hoped that such collaboration would be further
expanded so that more of their patent anti-cancer drugs can quickly
enter China, helping cancer sufferers and earning big profits from
the huge market.
Data from the State Food and Drug Administration indicated that
the sales of anti-cancer drugs reached US$1.2 billion last year and
are expected to reach US$1.7 billion next year.
China is rich in clinical experience, but medical research has
lagged behind developed countries due to a lack of funds, said
Sun.
However, the Chinese doctors have successfully integrated
traditional Chinese medicine with modern medicines in the treatment
of cancer and that has shown satisfactory results, said Sun.
One anti-cancer traditional Chinese medicine "Kanglaite," which
developed by a traditional medicine research institute in Zhejiang
Province, has been approved by the Food and Drug Administration of
the United States for clinical tests there, he said.
Sun, who is also an academician of the Chinese Academy of
Engineering, called for more support from all sectors to further
the integration of traditional and modern medicines in cancer
treatment.
He hopes the health authority will tighten up administration to
guarantee the healthy development of traditional Chinese
medicine.
(China Daily March 6, 2004)